TEST:

Hemarna™

Hemarna™ targets 232 fusion genes in hematolymphoid tumors. The test is used for early fusion screening for patients with hematolymphoid tumors (including acute lymphoblastic lymphoma, acute myeloid leukaemia, myeloproliferative neoplasms, and lymphomas); patients with hematolymphoid tumors but are ‘pan-negative’ or have non-classical fusions and require further fusion testing; and patients with specific fusion mutations undergoing dynamic monitoring after treatment or relapse.